Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by aclcmcon Feb 25, 2015 1:50pm

164 Views

Post# 23464199

RE:RE:RE:Lack of Updates Resverlogix and Zenith

FWIW, I received this note from the company earlier this month in response to my question/concern re: Zenith: "Thank you for your email. There is no timeframe on when the company will do an IPO. Current focus is to create value for the company. Zenith is targeting the second half of 2015 to file an IND for hematological malignancies and solid tumors. Zenith is committed to keeping their website up to date. Please visit www.zenithepigenetics.com to keep up to date."

Bullboard Posts

Eminent acquires promising Nevada gold project